Literature DB >> 17658634

Exercise-induced ST-segment elevation in leads aVR and V1 for the prediction of left main disease.

M Tuna Katircibaşi1, H Tolga Koçum, Abdullah Tekin, Tansel Erol, Göknur Tekin, Mehmet Baltali, Haldun Müderrisoğlu.   

Abstract

BACKGROUND: This study investigated the value of exercise-induced ST-segment elevation in lead aVR with or without concomitant ST-segment elevation in lead V(1) for detection of left main (LM) coronary artery disease in patients with Duke treadmill score <or=-11.
METHODS: One hundred and four patients with Duke treadmill score <or=-11 were retrospectively screened for presence of ST-segment elevation in lead aVR and lead V(1).
RESULTS: Twenty-six out of 65 patients with ST-segment elevation in lead aVR and 24 out 38 patients with ST-segment elevation in lead aVR with concomitant ST-segment elevation in lead V(1) were found to have LM disease. Exercise-induced ST-segment elevation in lead aVR had a sensitivity of 92.9% and a specificity of 48.6% and ST-segment elevation in lead aVR accompanied by ST-segment elevation in lead V(1) had a sensitivity of 85.7% and a specificity of 81.6% in predicting LM disease.
CONCLUSIONS: This study shows that the observation of exercise-induced ST-segment elevation in lead aVR is a sensitive, but not a specific, electrocardiographic finding of significant LM coronary artery disease. However, exercise-induced ST-segment elevation in lead aVR accompanied by ST-segment elevation in lead V(1) might be not only a sensitive but also a specific finding of LM stenosis in these patients.

Entities:  

Mesh:

Year:  2007        PMID: 17658634     DOI: 10.1016/j.ijcard.2007.05.022

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  9 in total

1.  aVR - the forgotten lead.

Authors:  Anil George; Pradeep S Arumugham; Vincent M Figueredo
Journal:  Exp Clin Cardiol       Date:  2010

Review 2.  Left main coronary artery disease: A review of the spectrum of noninvasive diagnostic modalities.

Authors:  Nishtha Sareen; Karthik Ananthasubramaniam
Journal:  J Nucl Cardiol       Date:  2015-10-20       Impact factor: 5.952

3.  Lead aVR: beyond 'No man's land'.

Authors:  Bhupinder Singh; Amjad Ali; Vivek Singla; Sadananda K Gowda
Journal:  BMJ Case Rep       Date:  2014-04-25

4.  Exercise test predictors of severe coronary artery disease: Role of ST-segment elevation in lead aVR.

Authors:  Giulio Russo; Salvatore Emanuele Ravenna; Antonio De Vita; Cristina Aurigemma; Priscilla Lamendola; Gaetano Antonio Lanza; Filippo Crea
Journal:  Clin Cardiol       Date:  2016-11-02       Impact factor: 2.882

Review 5.  Clinical utility of aVR-The neglected electrocardiographic lead.

Authors:  Dmitriy Kireyev; Mikhail V Arkhipov; Stephen T Zador; Joseph A Paris; William E Boden
Journal:  Ann Noninvasive Electrocardiol       Date:  2010-04       Impact factor: 1.468

6.  Value of ST-segment change in lead aVR in diagnosing left main disease in Non-ST-elevation acute coronary syndrome-A meta-analysis.

Authors:  Gien-Kuo Lee; Yen-Ping Hsieh; Shang-Wei Hsu; Shou-Jen Lan; Kshitij Soni
Journal:  Ann Noninvasive Electrocardiol       Date:  2019-09-18       Impact factor: 1.468

7.  Predictive Value of Exercise Stress Test-Induced ST-Segment Changes in Leads V1 and avR in Determining Angiographic Coronary Involvement.

Authors:  Samad Ghaffari; Reza Asadzadeh; Arezou Tajlil; Amirhossein Mohammadalian; Leili Pourafkari
Journal:  Ann Noninvasive Electrocardiol       Date:  2016-05-25       Impact factor: 1.468

8.  Exercise-Induced ST-Segment Elevation in Lead aVR as a Predictor of LCx Stenosis.

Authors:  M A Ostovan; A A Zolghadrasli
Journal:  Iran Red Crescent Med J       Date:  2011-12-01       Impact factor: 0.611

9.  Prevalence and Associated Clinical Characteristics of Exercise-Induced ST-Segment Elevation in Lead aVR.

Authors:  James McKinney; Ian Pitcher; Christopher B Fordyce; Masoud Yousefi; Tee Joo Yeo; Andrew Ignaszewski; Saul Isserow; Sammy Chan; Krishnan Ramanathan; Carolyn M Taylor
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.